Patents by Inventor Chung-Yi Wu

Chung-Yi Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250137725
    Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidasc (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
    Type: Application
    Filed: August 14, 2024
    Publication date: May 1, 2025
    Inventors: Chi-Huey WONG, Chung-Yi WU
  • Publication number: 20250114446
    Abstract: The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.
    Type: Application
    Filed: October 8, 2024
    Publication date: April 10, 2025
    Inventors: Chung-Yi WU, Jeng-Shin LEE, Chi-Huey WONG
  • Patent number: 12171824
    Abstract: The present disclosure relates to a composition for inducing immune response comprising a glycoengineered antibody or antigen-binding fragment thereof that is specific for an antigen portion having a receptor binding domain (RBD) of a surface protein of a virus. The present disclosure also relates to an immune combination and a method for treating an infection by a virus.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: December 24, 2024
    Assignee: CHO PHARMA, INC.
    Inventors: Chung-Yi Wu, Chien-Yu Chen, Ju-Mei Li, Kuo-Ching Chu
  • Publication number: 20240409570
    Abstract: Disclosed herein is a compound and its use for the prognosis or diagnosis of neurodegenerative diseases. The compound has the structure of formula (I), According to embodiments of the present disclosure, the neurodegenerative disease may be an Alzheimer's disease (AD), Parkinson disease (PD), Huntington's disease (HD), frontotemporal dementia (FTD), Friedreich's ataxia, age-related macular degeneration, or Creutzfeldt-Jakob disease.
    Type: Application
    Filed: September 8, 2022
    Publication date: December 12, 2024
    Inventors: Yun-Ru CHEN, Chung-Yi WU, Hwai-I YANG, Chiung-Mei CHEN, Pei-Ning WANG
  • Publication number: 20240366516
    Abstract: The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.
    Type: Application
    Filed: April 8, 2024
    Publication date: November 7, 2024
    Inventors: Chi-Huey Wong, Jeng Shin LEE, Chen-Yo FAN, Szu-Wen WANG, Chung-Yi WU
  • Publication number: 20240366517
    Abstract: The present disclosure provides novel compounds, methods, and cell targeting mRNA vaccine formulations for targeted delivery, such as delivery to dendritic cells. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features specific for dendritic cells and a lipid tail for incorporated into the bilayer membrane of the formed lipid nanoparticle.
    Type: Application
    Filed: April 8, 2024
    Publication date: November 7, 2024
    Inventors: Chi-Huey Wong, Jeng Shin LEE, Chen-Yo FAN, Szu-Wen WANG, Chung-Yi WU
  • Patent number: 12085340
    Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: September 10, 2024
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Publication number: 20240066113
    Abstract: The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof.
    Type: Application
    Filed: April 12, 2022
    Publication date: February 29, 2024
    Inventors: Chi-Huey WONG, Chung-Yi WU, Che MA, Chen-Yu FAN
  • Patent number: 11884739
    Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: January 30, 2024
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Ming-Hung Tsai
  • Publication number: 20230074185
    Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
    Type: Application
    Filed: September 20, 2022
    Publication date: March 9, 2023
    Inventors: Chi-Huey WONG, Chung-Yi WU
  • Patent number: 11480391
    Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 25, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 11377485
    Abstract: Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 5, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 11332523
    Abstract: The present disclosure relates to a novel class of anti-TNF? monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNF? IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNF? monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: May 17, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Publication number: 20220143172
    Abstract: The present disclosure relates to a composition for inducing immune response comprising a glycoengineered antibody or antigen-binding fragment thereof that is specific for an antigen portion having a receptor binding domain (RBD) of a surface protein of a virus. The present disclosure also relates to an immune combination and a method for treating an infection by a virus.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Inventors: Chung-Yi WU, Chien-Yu CHEN, Ju-Mei LI, Kuo-Ching CHU
  • Patent number: 11267870
    Abstract: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 8, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Publication number: 20210332146
    Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Application
    Filed: March 24, 2021
    Publication date: October 28, 2021
    Inventors: Chi-Huey WONG, Chung-Yi WU, Ming-Hung Tsai
  • Patent number: 11103567
    Abstract: Disclosed herein is a glycoconjugate vaccine conferring protection against a Gram negative pathogen infection, a method of manufacturing the glycoconjugate vaccine, and use of the glycoconjugate vaccine for treating bacterial infection. The glycoconjugate vaccine of the present disclosure has the structure of formula (I), wherein, L is a maleimide-type linker, which is connected to the carrier protein via a maleimide bond formed therebetween; and n and m are independently an integral or a non-integral number between 2 and 20.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 31, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Shih-Hsiung Wu, Chung-Yi Wu, I-Ming Lee, Feng-Ling Yang
  • Patent number: 11097000
    Abstract: The disclosure provides various immunogens comprising a repeat unit of saccharide of Klebsiella pneumoniae CPS, which has a formula selected from the group consisting of Formulae (I) to (VI) as described herein. Also provided are vaccines including one or more immunogens selected from Formula (I) to (VI) and methods of eliciting an immune response against a Klebsiella pneumoniae and preventing infection of Klebsiella pneumoniae by using an immunogen of the invention.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 24, 2021
    Assignees: NATIONAL TAIWAN UNIVERSITY, ACADEMIA SINICA
    Inventors: Jin-Town Wang, Shih-Hsiung Wu, Chung-Yi Wu
  • Publication number: 20200200758
    Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.
    Type: Application
    Filed: November 27, 2019
    Publication date: June 25, 2020
    Inventors: Chi-Huey WONG, Chung-Yi WU, Sarah K.C. CHEUNG, Po-Kai CHUANG, Tsui-Ling HSU
  • Publication number: 20200179503
    Abstract: Disclosed herein is a glycocojugate vaccine conferring protection against a Gram negative pathogen infection, a method of manufacturing the glycoconjugate vaccine, and use of the glycocojugate vaccine for treating bacterial infection. The glycocojugate vaccine of the present disclosure has the structure of formula (I), wherein, L is a maleimide-type linker, which is connected to the carrier protein via a maleimide bond formed therebetween; and n and m are respectively an integral or a non-integral number between 2 and 20.
    Type: Application
    Filed: June 14, 2019
    Publication date: June 11, 2020
    Inventors: Shih-Hsiung Wu, Chung-Yi Wu, I-Ming Lee, Feng-Ling Yang